I have been concerned that we don't really know how we are going to price those.

without the profit incentive, you will not get the innovation.

clearly, patents are part of the free market system, is the way that you protect intellectual property, and you incent creativity.

Let's make a difference for the people whom we represent--for those patients in hospitals who I once treated who otherwise would not have access to care.

Have you had a chance to evaluate the bill that is working its way through Judiciary Committee?

If you have got an initial high price, no matter what your value-based purchasing arrangement is, it could still be something which society could not afford.

I have been concerned that we don't really know how we are going to price those.

somebody is paying. Yes, insurance is making it more affordable. Medicaid is making it more affordable. Medicare is making it more affordable.

The people of Kansas sent me here to save Medicare.

Now, we have been discussing the promise of biosimilars to lower the cost in a market oriented, competitive way.

Very concisely, how are we going to show restraint on the price of some of these new gene therapies?

Let's make a difference for the people whom we represent--for those patients in hospitals who I once treated who otherwise would not have access to care.

without the profit incentive, you will not get the innovation.

If you have got an initial high price, no matter what your value-based purchasing arrangement is, it could still be something which society could not afford.

Now, value-based purchasing could obviously play a role here.

Let's just be clear, everybody on this panel cares about the high cost of prescription drugs and wants to work on real solutions to address this.

We support legislation in order to be able to do value based contracts in the case of gene therapy.

I have been concerned that we don't really know how we are going to price those.

clearly, patents are part of the free market system, is the way that you protect intellectual property, and you incent creativity.

For the sake of those who are watching, a rebate wall is an anti-competitive tool which can be used to restrict a competitor's entry into a formulary.

I think I recall a couple of years ago there was a study that was shown, respected, and you probably know it better than I, that $2 million for gene therapy for ultra-rare diseases was a reasonable sort of--it would cover the cost.

It is kind of following a formula. Republicans--we publicly attack private--I don't but others, publicly attack private citizens for being successful under capitalism.

We demand CEOs come before the Committee for public verbal stoning.

Now, the affordability though, we are defining affordability for the patient. So, if Medicaid covers it, it is by definition affordable for the patient, or if the insurance does.

Mr. Amin, have you had a chance to evaluate the bill that is working its way through Judiciary Committee?